Abstract
Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity). Owing to a marked heterogeneity of response to daratumumab therapy in MM, we investigated determinants of the sensitivity of MM cells toward daratumumab-mediated ADCC and CDC. In bone marrow samples from 144 MM patients, we observed no difference in daratumumab-mediated lysis between newly diagnosed or relapsed/refractory patients. However, we discovered, next to an expected effect of effector (natural killer cells/monocytes) to target (MM cells) ratio on ADCC, a significant association between CD38 expression and daratumumab-mediated ADCC (127 patients), as well as CDC (56 patients). Similarly, experiments with isogenic MM cell lines expressing different levels of CD38 revealed that the level of CD38 expression is an important determinant of daratumumab-mediated ADCC and CDC. Importantly, all-trans retinoic acid (ATRA) increased CD38 expression levels but also reduced expression of the complement-inhibitory proteins CD55 and CD59 in both cell lines and primary MM samples. This resulted in a significant enhancement of the activity of daratumumab in vitro and in a humanized MM mouse model as well. Our results provide the preclinical rationale for further evaluation of daratumumab combined with ATRA in MM patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2010; 37: 266–283.
van de Donk NW, Kamps S, Mutis T, Lokhorst HM . Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012; 26: 199–213.
Laubach JP, Tai YT, Richardson PG, Anderson KC . Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs 2014; 23: 445–452.
Dolgin E . Cancer's true breakthroughs. Nat Med 2013; 19: 660–663.
Deaglio S, Mehta K, Malavasi F . Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1–12.
Malavasi F . Editorial: CD38 and retinoids: a step toward a cure. J Leukoc Biol 2011; 90: 217–219.
Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010; 24: 958–969.
Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N . CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011; 118: 3470–3478.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.
Jansen JHM, Boross P, Overdijk MB, van Bueren JJL, Parren PWHI, Leusen JHW . Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. ASH Annu Meet Abstr 2012; 120: 2974.
Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012; 120: e9–e16.
Noort WA, Groen RWJ, Raymakers R, Aalders L, Hofhuis FM, van Kessel B et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of refractory patient-derived multiple myeloma cells, growing in a novel humanized mouse MM model. ASH Annu Meet Abstr 2012; 120: 940.
Lokhorst H, Laubach JP, Nahi H, Plesner T, Gimsing P, Hansson M et al. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). J Clin Oncol 2014; 32: 8513.
van der Veer M, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284–290.
Nijhof IS, van Noort W, Lammerts van Bueren J, van Kessel B, Bakker J, Parren P et al. CD38-targeted immunochemotherapy of multiple myeloma: preclinical evidence for its combinatorial use in lenalidomide and bortezomib refractory/intolerant MM patients. Blood 2013; 122: 277.
Nijhof IS, Groen RW, Noort WA, van KB, de Jong-Korlaar RA, Bakker JM et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2014.
Plesner T, Arkenau T, Lokhorst H, Gimsing P, Krejcik J, Lemech C et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Blood 2013; 122: 1986.
Plesner T, Arkenau T, Lokhorst HM, Gimsing P, Krejcik J . Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 2014; 124: 84.
van der Veer M, de Weers M, van KB, Bakker JM, Wittebol S, Parren PW et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011; 1: e41.
Nijhof IS, de Weers M, Andre P, van Kessel B, Lokhorst HM, Parren PWHI et al. Synergistic action of the human inhibitory KIR antibody IPH2102, and the human CD38 antibody daratumumab to enhance the lysis of primary multiple myeloma (MM) cells in the bone marrow mononuclear cells (MNCs) from myeloma patients. ASH Annu Meet Abstr 2011; 118: 1865.
de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res 2013; 19: 5591–5601.
Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ et al. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res 1994; 54: 1746–1752.
Meyer S, Leusen JH, Boross P . Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs 2014; 6: 1133–1144.
van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB . Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12: 4027–4035.
Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389.
Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X et al. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 6702–6711.
Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res 2009; 15: 3624–3632.
Suzuki Y, Yoshida T, Wang G, Togano T, Miyamoto S, Miyazaki K et al. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Ann Hematol 2012; 91: 997–1005.
Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 3773–3780.
Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012; 7: e39416.
Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013; 141: 43–53.
Lipton A, Kostler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010; 116: 5168–5178.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286–2294.
Balmer JE, Blomhoff R . Gene expression regulation by retinoic acid. J Lipid Res 2002; 43: 1773–1808.
Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, Chikamatsu Y et al. All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta. J Leukoc Biol 2011; 90: 235–247.
Kishimoto H, Hoshino S, Ohori M, Kontani K, Nishina H, Suzawa M et al. Molecular mechanism of human CD38 gene expression by retinoic acid. Identification of retinoic acid response element in the first intron. J Biol Chem 1998; 273: 15429–15434.
Lewandowski D, Linassier C, Iochmann S, Degenne M, Domenech J, Colombat P et al. Phosphatidylinositol 3-kinases are involved in the all-trans retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells. Br J Haematol 2002; 118: 535–544.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
KS and PD are employees of Janssen Pharmaceuticals. HML,TM, ACM and NWCJvdD received research support from Janssen Pharmaceuticals. All other authors declared no conflicts of interest.
Additional information
Author Contributions
IN, RWJG, JvV, RdJ-K, WAN and BvK executed the experiments, analyzed and interpreted the results. KS and PD provided daratumumab. HY developed and provided the scaffolds for the mouse experiments. HML, SK and NWCJvdD provided patient materials. TM, ACMM, HML and NWCJvdD designed the study and interpreted the results. IN and NWCJvdD wrote the first draft of the manuscript. All authors helped critically review the manuscript and checked the final version of it.
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Nijhof, I., Groen, R., Lokhorst, H. et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29, 2039–2049 (2015). https://doi.org/10.1038/leu.2015.123
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.123
This article is cited by
-
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Nature Communications (2024)
-
Cell surface GRP78: a potential mechanism of therapeutic resistant tumors
Cancer Cell International (2023)
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies
Journal of Experimental & Clinical Cancer Research (2022)
-
Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
Scientific Reports (2022)
-
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Annals of Hematology (2022)